These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 23228017)
21. Neoadjuvant Treatment with Angiogenesis-Inhibitor Dovitinib Prior to Local Therapy in Hepatocellular Carcinoma: A Phase II Study. Woei-A-Jin FJSH; Weijl NI; Burgmans MC; Fariña Sarasqueta A; van Wezel JT; Wasser MNJM; Coenraad MJ; Burggraaf J; Osanto S Oncologist; 2021 Oct; 26(10):854-864. PubMed ID: 34251745 [TBL] [Abstract][Full Text] [Related]
22. Inhibition of eukaryotic initiation factor 4E phosphorylation by cercosporamide selectively suppresses angiogenesis, growth and survival of human hepatocellular carcinoma. Liu Y; Sun L; Su X; Guo S Biomed Pharmacother; 2016 Dec; 84():237-243. PubMed ID: 27662474 [TBL] [Abstract][Full Text] [Related]
23. Prostate cancer cell-stromal cell crosstalk via FGFR1 mediates antitumor activity of dovitinib in bone metastases. Wan X; Corn PG; Yang J; Palanisamy N; Starbuck MW; Efstathiou E; Li Ning Tapia EM; Zurita AJ; Aparicio A; Ravoori MK; Vazquez ES; Robinson DR; Wu YM; Cao X; Iyer MK; McKeehan W; Kundra V; Wang F; Troncoso P; Chinnaiyan AM; Logothetis CJ; Navone NM Sci Transl Med; 2014 Sep; 6(252):252ra122. PubMed ID: 25186177 [TBL] [Abstract][Full Text] [Related]
24. Antitumor and Antiangiogenic Activities of Lenvatinib in Mouse Xenograft Models of Vascular Endothelial Growth Factor-Induced Hypervascular Human Hepatocellular Carcinoma. Adachi Y; Matsuki M; Watanabe H; Takase K; Kodama K; Matsui J; Funahashi Y; Nomoto K Cancer Invest; 2019; 37(4-5):185-198. PubMed ID: 31006280 [TBL] [Abstract][Full Text] [Related]
25. Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. Brands RC; Knierim LM; De Donno F; Steinacker V; Hartmann S; Seher A; Kübler AC; Müller-Richter UDA Oncol Rep; 2017 Sep; 38(3):1877-1885. PubMed ID: 28714017 [TBL] [Abstract][Full Text] [Related]
26. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model. Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167 [TBL] [Abstract][Full Text] [Related]
28. Small molecule R1498 as a well-tolerated and orally active kinase inhibitor for hepatocellular carcinoma and gastric cancer treatment via targeting angiogenesis and mitosis pathways. Zhang C; Wu X; Zhang M; Zhu L; Zhao R; Xu D; Lin Z; Liang C; Chen T; Chen L; Ren Y; Zhang J; Qin N; Zhang X PLoS One; 2013; 8(6):e65264. PubMed ID: 23755206 [TBL] [Abstract][Full Text] [Related]
29. ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft. Jasinghe VJ; Xie Z; Zhou J; Khng J; Poon LF; Senthilnathan P; Glaser KB; Albert DH; Davidsen SK; Chen CS J Hepatol; 2008 Dec; 49(6):985-97. PubMed ID: 18930332 [TBL] [Abstract][Full Text] [Related]
30. Sunitinib acts primarily on tumor endothelium rather than tumor cells to inhibit the growth of renal cell carcinoma. Huang D; Ding Y; Li Y; Luo WM; Zhang ZF; Snider J; Vandenbeldt K; Qian CN; Teh BT Cancer Res; 2010 Feb; 70(3):1053-62. PubMed ID: 20103629 [TBL] [Abstract][Full Text] [Related]
31. Phase I study of dovitinib (TKI258), an oral FGFR, VEGFR, and PDGFR inhibitor, in advanced or metastatic renal cell carcinoma. Angevin E; Lopez-Martin JA; Lin CC; Gschwend JE; Harzstark A; Castellano D; Soria JC; Sen P; Chang J; Shi M; Kay A; Escudier B Clin Cancer Res; 2013 Mar; 19(5):1257-68. PubMed ID: 23339124 [TBL] [Abstract][Full Text] [Related]
33. Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. Huynh H; Ngo VC; Choo SP; Poon D; Koong HN; Thng CH; Toh HC; Zheng L; Ong LC; Jin Y; Song IC; Chang AP; Ong HS; Chung AY; Chow PK; Soo KC Curr Cancer Drug Targets; 2009 Sep; 9(6):738-47. PubMed ID: 19754358 [TBL] [Abstract][Full Text] [Related]
34. Dovitinib synergizes with oxaliplatin in suppressing cell proliferation and inducing apoptosis in colorectal cancer cells regardless of RAS-RAF mutation status. Gaur S; Chen L; Ann V; Lin WC; Wang Y; Chang VH; Hsu NY; Shia HS; Yen Y Mol Cancer; 2014 Feb; 13():21. PubMed ID: 24495750 [TBL] [Abstract][Full Text] [Related]
35. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as Imaging Biomarker for Vascular Normalization Effect of Infigratinib in High-FGFR-Expressing Hepatocellular Carcinoma Xenografts. Tran A; Koh TS; Prawira A; Ho RZW; Le TBU; Vu TC; Hartano S; Teo XQ; Chen WC; Lee P; Thng CH; Huynh H Mol Imaging Biol; 2021 Feb; 23(1):70-83. PubMed ID: 32909245 [TBL] [Abstract][Full Text] [Related]
36. Antitumoral effects of dovitinib in triple-negative breast cancer are synergized by calcitriol in vivo and in vitro. García-Quiroz J; Cárdenas-Ochoa N; García-Becerra R; Morales-Guadarrama G; Méndez-Pérez EA; Santos-Cuevas C; Ramírez-Nava GJ; Segovia-Mendoza M; Prado-García H; Avila E; Larrea F; Díaz L J Steroid Biochem Mol Biol; 2021 Nov; 214():105979. PubMed ID: 34438041 [TBL] [Abstract][Full Text] [Related]
37. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells. Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976 [TBL] [Abstract][Full Text] [Related]
38. Choline Kinase α Mediates Interactions Between the Epidermal Growth Factor Receptor and Mechanistic Target of Rapamycin Complex 2 in Hepatocellular Carcinoma Cells to Promote Drug Resistance and Xenograft Tumor Progression. Lin XM; Hu L; Gu J; Wang RY; Li L; Tang J; Zhang BH; Yan XZ; Zhu YJ; Hu CL; Zhou WP; Li S; Liu JF; Gonzalez FJ; Wu MC; Wang HY; Chen L Gastroenterology; 2017 Apr; 152(5):1187-1202. PubMed ID: 28065789 [TBL] [Abstract][Full Text] [Related]
39. Evodiamine exerts anti-tumor effects against hepatocellular carcinoma through inhibiting β-catenin-mediated angiogenesis. Shi L; Yang F; Luo F; Liu Y; Zhang F; Zou M; Liu Q Tumour Biol; 2016 Sep; 37(9):12791-12803. PubMed ID: 27449032 [TBL] [Abstract][Full Text] [Related]